Brokerages Set Haemonetics Corporation (NYSE:HAE) PT at $97.89

Shares of Haemonetics Corporation (NYSE:HAE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $97.89.

A number of equities analysts have commented on HAE shares. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Raymond James Financial reissued a "strong-buy" rating and issued a $105.00 price target (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC reduced their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Finally, JMP Securities reissued a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th.

Haemonetics Stock Down 1.4%

NYSE HAE traded down $0.96 during midday trading on Friday, hitting $69.00. 548,078 shares of the company traded hands, compared to its average volume of 678,150. The company's 50-day simple moving average is $65.61 and its 200-day simple moving average is $68.79. Haemonetics has a 52 week low of $55.30 and a 52 week high of $94.99. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The company has a market cap of $3.31 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.13 and a beta of 0.36.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. Haemonetics's revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.90 EPS. As a group, equities research analysts forecast that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Investors Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. acquired a new position in Haemonetics in the 4th quarter valued at $25,000. Quarry LP boosted its holdings in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. Covestor Ltd increased its position in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. bought a new stake in shares of Haemonetics in the 4th quarter valued at approximately $62,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in Haemonetics during the first quarter worth about $65,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.